Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Phase 2 Completed
84 enrolled
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
Phase 2 Completed
107 enrolled 11 charts
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
Phase 2 Completed
40 enrolled
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
Phase 2 Completed
5 enrolled 10 charts
An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis
Phase 2 Completed
260 enrolled 4 charts
Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Completed
31 enrolled
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Completed
140 enrolled
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
Phase 2 Completed
213 enrolled 19 charts
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
Phase 2 Completed
28 enrolled 10 charts
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
Phase 2 Completed
20 enrolled 11 charts
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Completed
210 enrolled 15 charts
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Phase 2 Completed
42 enrolled
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers
Phase 2 Completed
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
77 enrolled 12 charts
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
14 enrolled 22 charts
Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer
Phase 2 Completed
142 enrolled 11 charts
CML0206
Phase 2 Completed
57 enrolled 5 charts
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Phase 2 Completed
39 enrolled 12 charts
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
Phase 2 Completed
49 enrolled 4 charts
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
Phase 2 Completed
43 enrolled 14 charts
MINI HEME
Phase 2 Completed
25 enrolled
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
Phase 2 Completed
204 enrolled 7 charts
Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies
Phase 2 Completed
23 enrolled
Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Phase 2 Completed
151 enrolled 3 charts
Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant
Phase 2 Completed
12 enrolled 6 charts
Investigation of Clofarabine in Acute Leukemias
Phase 2 Completed
64 enrolled
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
Phase 2 Completed
35 enrolled 8 charts
Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment
Phase 2 Completed
70 enrolled
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase 2 Completed
34 enrolled 16 charts
Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS
Phase 2 Completed
30 enrolled 8 charts
Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
Phase 2 Completed
60 enrolled
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
Phase 2 Completed
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer
Phase 2 Completed
111 enrolled
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
Phase 2 Completed
Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Completed
30 enrolled
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia
Phase 2 Completed
High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors
Phase 2 Completed
451 enrolled
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
Phase 2 Completed
40 enrolled
Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer
Phase 2 Completed
52 enrolled
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer
Phase 2 Completed
STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis
Phase 2 Completed
Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Completed
80 enrolled
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
Phase 2 Completed
74 enrolled
Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
Phase 2 Completed
72 enrolled
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
Phase 2 Completed
24 enrolled 13 charts
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
Phase 2 Completed
171 enrolled
Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia
Phase 2 Completed
53 enrolled
Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic Syndrome
Phase 2 Completed
54 enrolled
Non-Ablative Allo HSCT For Hematologic Malignancies or SAA
Phase 2 Completed
58 enrolled
Chemotherapy Plus Radiation Therapy and Biological Therapy in Treating Patients With Hematologic Cancer
Phase 2 Completed
50 enrolled